Articles
Enhancing process safety and efficiency in the pharmaceutical industry with check Weighing solutions
A look at how pharmaceutical manufacturers can benefit from the use of dynamic checkweighing technology to comply with international standards, increase process safety, productivity and process control.
The need for pharmaceutical manufacturers to rely on technological advancements has never been greater....
Articles
ViscoTec Pharma Dispenser VPHD on the test
With nearly 140 years of success, Henkel holds globally leading market positions both in the consumer and industrial sectors and is well known for brands such as Persil, Schwarzkopf and Loctite. In itsworldwide operating business area“Laundry & Home Care”,Henkel...
Articles
Biofortuna reaches key milestones for ReadyPlex blood group
Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has successfully achieved key milestones in the development of its new blood group genotyping product family ReadyPlex™. This breakthrough has released the...
Research Insight
Boehringer Ingelheim and Harvard scientists establish a research alliance
Boehringer Ingelheim announced it has established a research collaboration with the Harvard Stem Cell Institute’s - Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic...
Research Insight
Mylan Launches First Generic of Nuvigil Tablets
Mylan N.V. announced the U.S. launch of Armodafinil Tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephalon's Nuvigil®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application...
Research Insight
Allergan Announces Positive Pivotal Trial Results for Oculeve Intranasal Tear Neurostimulator
Allergan plc announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met their primary and secondary efficacy endpoints. With these new results, a premarket submission for the device is on-track to be submitted...
Research Insight
Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis
Chugai Pharmaceutical Co Ltd announced that "Actemra® Subcutaneous Injection" (Actemra), the humanized antihuman IL-6 receptor monoclonal antibody, successfully met the primary endpoint in a dose interval reduction study (MRA231JP study) conducted in patients with rheumatoid arthritis who inadequately respond...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read